Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Mallinckrodt
Express Scripts
Dow
AstraZeneca

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ROPIVACAINE HYDROCHLORIDE

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for Ropivacaine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00130091 The Addition of Clonidine to 0.2% Ropivacaine for Wound Instillation After Minor Lower Abdominal Surgery in Children Completed Children's Hospital of Eastern Ontario Phase 2 2009-09-01 The current study will compare the effects on postoperative pain relief of "freezing" (ropivacaine 0.2 %) alone and in combination with clonidine for a nerve block in children undergoing hernia repair. The researchers anticipate that the addition of clonidine to "freezing" will result in prolongation of postoperative pain relief in children undergoing hernia repair compared to "freezing" used alone.
NCT00150865 Evaluation of Efficacy of Lumbar Plexus Bloc After Hip Surgery Completed University Hospital, Angers N/A 2001-09-01 Compare lumbar plexus block with ropivacaine 0.475%, 0.4 ml/kg to saline. Each group randomized, includes 30 patients. block performed preoperatively Surgery under general anesthesia. Postoperative evaluation of pain (VAS) as first endpoint, and also morphine consumption via PCA device. Follow-up : 24h. Expectation : sizeable reduction of pain with block, of duration.
NCT00197340 Antepartum Chronic Epidural Therapy (ACET) to Improve Blood Flow to the Uterus, Placenta and Baby in Pre-Eclampsia and Intrauterine Growth Restriction Completed International Anesthesia Research Society (IARS) Phase 3 2003-08-01 Pre-eclampsia (PE) and intrauterine growth restriction (IUGR) are common and important disorders of pregnancy. Both disorders are associated with an impairment of uteroplacental blood flow (UPBF). No effective therapy has been identified to reliably improve UPBF in these patients and typically, obstetric management involves interventional delivery, particularly problematic when remote from term. This study assess the hypothesis that epidural local anesthetics may improve UPBF in these patients.
NCT00197340 Antepartum Chronic Epidural Therapy (ACET) to Improve Blood Flow to the Uterus, Placenta and Baby in Pre-Eclampsia and Intrauterine Growth Restriction Completed Hadassah Medical Organization Phase 3 2003-08-01 Pre-eclampsia (PE) and intrauterine growth restriction (IUGR) are common and important disorders of pregnancy. Both disorders are associated with an impairment of uteroplacental blood flow (UPBF). No effective therapy has been identified to reliably improve UPBF in these patients and typically, obstetric management involves interventional delivery, particularly problematic when remote from term. This study assess the hypothesis that epidural local anesthetics may improve UPBF in these patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ropivacaine Hydrochloride

Condition Name

Condition Name for Ropivacaine Hydrochloride
Intervention Trials
Pain, Postoperative 76
Postoperative Pain 67
Pain 63
Total Knee Arthroplasty 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ropivacaine Hydrochloride
Intervention Trials
Pain, Postoperative 178
Osteoarthritis 31
Fractures, Bone 30
Osteoarthritis, Knee 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ropivacaine Hydrochloride

Trials by Country

Trials by Country for Ropivacaine Hydrochloride
Location Trials
United States 159
France 64
Denmark 50
Canada 39
China 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ropivacaine Hydrochloride
Location Trials
California 22
Ohio 19
Pennsylvania 17
Texas 11
New York 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ropivacaine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Ropivacaine Hydrochloride
Clinical Trial Phase Trials
Phase 4 255
Phase 3 84
Phase 2/Phase 3 16
[disabled in preview] 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ropivacaine Hydrochloride
Clinical Trial Phase Trials
Completed 222
Recruiting 163
Not yet recruiting 129
[disabled in preview] 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ropivacaine Hydrochloride

Sponsor Name

Sponsor Name for Ropivacaine Hydrochloride
Sponsor Trials
Zealand University Hospital 12
Duke University 9
University of California, San Diego 9
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ropivacaine Hydrochloride
Sponsor Trials
Other 747
Industry 31
U.S. Fed 7
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Baxter
Merck
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.